Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lonza

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

Bristol-Myers Squibb (BMS) building

BMS adds another Ono drug to its immuno-oncology portfolio

Pharma giant hopes its new candidate can follow in the footsteps of Opdivo

Bristol Myers Squibb logo

Bad news for Innate Pharma as BMS-backed drug stumbles

Lirilumab combination fails to show additional benefit in SCCHN patients

Bristol-Myers Squibb (BMS) building

BMS adds another EU indication to Opdivo’s growing list

Wins European licence to treat high-risk advanced melanoma

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

Better kidney cancer symptom control reported versus sunitinib was also reported

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo defies naysayers with healthy growth

Third quarter sales of the PD1 inhibitor saw a 38% rise

- PMLiVE

BMS appoints Saurabh Saha as senior VP, global head of translational medicine

He joins the R&D team from Atlas Venture

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

Bristol-Myers Squibb (BMS) building

BMS data add to checkpoint inhibitor combo confusion

Opdivo and Yervoy meet one objective but miss another in CheckMate-214

Bristol-Myers Squibb (BMS) building

BMS boosts immuno-oncology with $2.3bn IFM buy

Boston-based group will operate as a subsidiary of BMS

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links